Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction
Journal of Cardiovascular Pharmacology and Therapeutics · 2024
DOI: 10.1177/10742484241301191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2024. Verfasst von Jun Wan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Internal Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Ventricular Remodeling, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Ventricular Function, Left. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To assess the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) on cardiac remodeling and prognosis in type 2 diabetes mellitus (T2DM) patients presenting with acute myocardial infarction (AMI).
Methods
In this single-center retrospective active-comparator study, consecutive diabetic AMI patients undergoing percutaneous coronary intervention (PCI) between 2021 and 2023 were enrolled. Patients were divided into SGLT2-I users and non-SGLT2-I users based on discharge medications. The primary endpoint was the left ventricular remodeling index (LVRI), defined as the relative change in LV end-diastolic volume after six months. The secondary outcomes included major adverse cardiovascular events (MACE), comprising all-cause mortality, hospitalization for heart failure, nonfatal MI, and nonfatal stroke.
Results
The study comprised 423 T2DM AMI patients(with or without ST-segment elevation), with 239 SGLT2-I users and 184 non-SGLT2-I users. At six months, LVRI was significantly lower in the SGLT2-I users compared to the non-SGLT2-I users (3.49 ± 19.71 vs 7.06 ± 15.15, P = .042). The non-SGLT2-I users exhibited a higher prevalence of positive LVR (LVRI > 0%) (64.67% vs 50.63%, P = .004) and pathological LVR (LVRI > 20%) (19.57% vs 12.13%, P = .036). Multivariate logistic regression indicated that SGLT2-I was associated with a reduced risk of LVR (OR 0.6; 95%CI 0.38-0.97; P = .035). During a mean follow-up of 25 ± 8 months, Kaplan-Meier analysis demonstrated a lower rate of MACE-free survival in the non-SGLT2-I users ( P = .005).
Conclusions
SGLT2-I protects against LVR and lowers the risk of adverse cardiovascular outcomes in T2DM AMI patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Internal Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Electrocardiographic Diagnosis, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Emergency Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
ORCID-Profile: Jun Wan, Feng Xu, Jinglin Cheng
Zitieren
APA
Wan, J., Xu, F., Zuo, H., Jiang, X., Wang, Y., Jiang, Y., Chen, C., Yin, C., Cheng, J., & Li, H. (2024). Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484241301191
Vancouver
Wan J, Xu F, Zuo H, Jiang X, Wang Y, Jiang Y, et al. Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics. 2024. doi:10.1177/10742484241301191
BibTeX
@article{Wan2024,
author = {Wan, Jun and Xu, Feng and Zuo, Heping and Jiang, Xin and Wang, Yulin and Jiang, Yang and Chen, Cai and Yin, Chunlin and Cheng, Jinglin and Li, He},
title = {Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2024},
doi = {10.1177/10742484241301191}
}
EUVIMED